Carsten Eggers1,2, R Dano3, J Schill3, G R Fink3,4, M Hellmich5, L Timmermann3,6. 1. Department of Neurology, University of Cologne, Cologne, Germany. carsten.eggers@uk-gm.de. 2. Department of Neurology, University Hospital Marburg, Philipps-University of Marburg, Baldingerstr., 35043, Marburg, Germany. carsten.eggers@uk-gm.de. 3. Department of Neurology, University of Cologne, Cologne, Germany. 4. Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Jülich, Germany. 5. Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany. 6. Department of Neurology, University Hospital Marburg, Philipps-University of Marburg, Baldingerstr., 35043, Marburg, Germany.
Abstract
INTRODUCTION:Improving quality of life (QoL) is a key issue when dealing with Parkinson's disease (PD). Integrative care shows potential to achieve improvements in QoL. Here, we analyzed whether a community-based, open-label, integrated approach improves QoL in PD patients. METHODS:PD patients were screened for eligibility and evaluated by a university-based PD specialist, a PD nurse, and a general neurologist at a local practice. Patients were randomly assigned to a control group (CG), receiving standard German neurological treatment including a baseline assessment and follow-up visit at 6 months, or an interventional group (IG) who received an individually tailored therapy plan and additional home visits. Patients and investigators were not blinded for either intervention. Primary outcome analysis compared the differential change of PDQ-39 from baseline to 6-month follow-up between CG and IG. Between-group changes in mood, motor/non-motor functioning, and cognition were secondary outcomes. RESULTS:300 patients were included and randomized equally to IG and CG. 132 IG and 125 CG patients had a valid PDQ-39 at follow-up and qualified for the modified ITT analysis. PDQ-39 improved more in IG compared to CG [2.2 points (95% CI - 4.4 to 0.1); p = 0.044]. Likewise, change scores between IG and CG favored IG for UPDRS III (p < 0.001, mean change 3.3, 95% CI - 4.9 to - 1.7) and PD-NMS (p < 0.001, mean change 11.3, 95% CI - 17.1 to - 5.5). CONCLUSIONS: Data show that an integrated approach, compared to regular PD care, improves QoL as well as motor and nonmotor PD symptoms over 6 months. Future studies need to address the cost-benefit ratio and whether positive effects can be maintained beyond intervention.
RCT Entities:
INTRODUCTION: Improving quality of life (QoL) is a key issue when dealing with Parkinson's disease (PD). Integrative care shows potential to achieve improvements in QoL. Here, we analyzed whether a community-based, open-label, integrated approach improves QoL in PDpatients. METHODS:PDpatients were screened for eligibility and evaluated by a university-based PD specialist, a PD nurse, and a general neurologist at a local practice. Patients were randomly assigned to a control group (CG), receiving standard German neurological treatment including a baseline assessment and follow-up visit at 6 months, or an interventional group (IG) who received an individually tailored therapy plan and additional home visits. Patients and investigators were not blinded for either intervention. Primary outcome analysis compared the differential change of PDQ-39 from baseline to 6-month follow-up between CG and IG. Between-group changes in mood, motor/non-motor functioning, and cognition were secondary outcomes. RESULTS: 300 patients were included and randomized equally to IG and CG. 132 IG and 125 CG patients had a valid PDQ-39 at follow-up and qualified for the modified ITT analysis. PDQ-39 improved more in IG compared to CG [2.2 points (95% CI - 4.4 to 0.1); p = 0.044]. Likewise, change scores between IG and CG favored IG for UPDRS III (p < 0.001, mean change 3.3, 95% CI - 4.9 to - 1.7) and PD-NMS (p < 0.001, mean change 11.3, 95% CI - 17.1 to - 5.5). CONCLUSIONS: Data show that an integrated approach, compared to regular PD care, improves QoL as well as motor and nonmotor PD symptoms over 6 months. Future studies need to address the cost-benefit ratio and whether positive effects can be maintained beyond intervention.
Entities:
Keywords:
Allied health; Integrated care; Multidisciplinary; Parkinson; Quality of life
Authors: Pablo Martinez-Martin; Martine Jeukens-Visser; Kelly E Lyons; C Rodriguez-Blazquez; Caroline Selai; Andrew Siderowf; Mickie Welsh; Werner Poewe; Oliver Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz; Anette Schrag Journal: Mov Disord Date: 2011-07-06 Impact factor: 10.338
Authors: Marjolein A van der Marck; Bastiaan R Bloem; George F Borm; Sebastiaan Overeem; Marten Munneke; Mark Guttman Journal: Mov Disord Date: 2012-11-19 Impact factor: 10.338
Authors: Sonja von Campenhausen; Yaroslav Winter; Antonio Rodrigues e Silva; Christina Sampaio; Evzen Ruzicka; Paolo Barone; Werner Poewe; Alla Guekht; Céu Mateus; Karl-P Pfeiffer; Karin Berger; Jana Skoupa; Kai Bötzel; Sabine Geiger-Gritsch; Uwe Siebert; Monika Balzer-Geldsetzer; Wolfgang H Oertel; Richard Dodel; Jens P Reese Journal: Eur Neuropsychopharmacol Date: 2011-02 Impact factor: 4.600
Authors: Marjolein A van der Marck; Marten Munneke; Wim Mulleners; Edo M Hoogerwaard; George F Borm; Sebastiaan Overeem; Bastiaan R Bloem Journal: Lancet Neurol Date: 2013-08-27 Impact factor: 44.182
Authors: Martijn van der Eijk; Bastiaan R Bloem; Frouke A P Nijhuis; Jan Koetsenruijter; Hubertus J M Vrijhoef; Marten Munneke; Michel Wensing; Marjan J Faber Journal: J Parkinsons Dis Date: 2015 Impact factor: 5.568
Authors: Jacqueline A Osborne; Rachel Botkin; Cristina Colon-Semenza; Tamara R DeAngelis; Oscar G Gallardo; Heidi Kosakowski; Justin Martello; Sujata Pradhan; Miriam Rafferty; Janet L Readinger; Abigail L Whitt; Terry D Ellis Journal: Phys Ther Date: 2022-04-01
Authors: Carsten Eggers; Richard Dano; Juliane Schill; Gereon R Fink; Lars Timmermann; Raymond Voltz; Heidrun Golla; Stefan Lorenzl Journal: Front Neurol Date: 2018-07-30 Impact factor: 4.003
Authors: Angelika D van Halteren; Marten Munneke; Eva Smit; Sue Thomas; Bastiaan R Bloem; Sirwan K L Darweesh Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568
Authors: Bastiaan R Bloem; Emily J Henderson; E Ray Dorsey; Michael S Okun; Njideka Okubadejo; Piu Chan; John Andrejack; Sirwan K L Darweesh; Marten Munneke Journal: Lancet Neurol Date: 2020-11 Impact factor: 59.935